EUREKA
Institute

International Certificate Program
May 11th - May 17th 2014
Siracusa, Italy

EUREKA INSTITUTE™
for translational medicine

EUREKA
Institute

International Certificate Program
May 11th - May 17th 2014
Siracusa, Italy

The Three Pillars

The Eureka educational initiative is based on:

- an attitude of teamwork
- critical thinking skills
- knowledge of translational medicine

Eureka's mission

The Institute's mission is to develop a community of translational medicine professionals equipped to catalyze the application of discoveries for the benefit of human health. We do this by educating and building a community.

Overall Educational Objectives

Participants in the Certificate Program will:

1. Analyze the business, scientific and regulatory aspects of Translational Medicine (TM)
2. Explore the challenges professionals encounter in TM
3. Develop critical thinking skills to approach the challenges in Translational Medicine
4. Develop communication skills for presenting various topics to a broad spectrum of people
5. Analyze effective manuscript preparation and begin to apply the concepts to their own work

Educational Strategies

We use a number of educational strategies to achieve the overall course objectives and the goals of each individual activity. Key among these is creating an open and safe environment through which participants can navigate, and in which participants may interact.

Support

We thank the kind support of the Immunity & Techology Stichting Center for Translational Molecular Medicine (CTMM), Danone Nutricia Research B.V., the University of Arizona – Parent Project Muscular Dystrophy, RUSH University, EUTRAIN, the University of Toronto - Institute of Medical Science, Nature Medicine, Nature Medicine Biotechnology, the University College London, University Medical Center Utrecht – Child Health Program, SingHealth Services, Duke – NUS Graduate Medical School,and the University Medical Center Utrecht, Dutch Artritis Foundation.

We deeply appreciate the Faculty for the 2014 International Certificate Program. They are generously donating their time and expertise to participate in the course. Our sincere gratitude goes to Julia Ong, who provides energy and cohesion to this Program. We want to recognize the dedicate effort and commitment of the Acute Frog Consulting team, Marco Abate and Bob Chinello. We thank Erica Roks and Dasha Gakh for their contributions. In addition, we thank our Artists-in-Residence Anna van Suchtelen and Brian Goeltzenleuchter for contributing their time and passion in cultivating the 2014 Translational Creativity program. We are deeply indebted to Jessica Colomb for her creative and passionate contribution towards the birth and growth of Eureka to-date. Lastly, we thank Francesco Italia, Vittorio di Natale, and their colleagues at the Borgia del Casale for their extraordinary efforts, gastronomic artistry, and for the beautiful space in which the course is held.

Eureka Board 2014: Salvo Albani, David Hafler, Janet Hafler, Juan Carlos Lopez, Jan Vos van Marken, Berent Prakken, Norm Rosenblum, Vicki Seyfert-Margolis.

2009 Participants and Faculty

Edited and compiled by The Eureka Institute for Translational Medicine

A publication of the Eureka Institute for Translational Medicine. Prepared in the partial fulfillment of the requirements for the certificate of completion. Continuing Medical Education credits are not being offered for this course, however the materials are in compliance with the requirements of the Accreditation Council for Continuing Medical Education. Course materials and handouts include edited and compiled works of multiple authors.

Requests for reprints or reproduction to:
Eureka Institute for Translational Medicine
c/o Ms Julia Ong
The Academia, Discovery Tower Level 8
20 College Road
Singapore 169856
info@eurekainstitute.org

Photos contributed by Jessica Colomb and Ingrid Lether

About Translational Medicine

Today, the term "translational medicine" is a buzzword in biomedical sciences with a rapidly increasing number of meetings about it; courses on it; and institutes dedicated to it. A simple Pubmed search on "translational medicine" generates over 37,000 papers, while a Google search yields nearly 24,000,000 hits. Because of its popularity and its increased use, the meaning of the term translational medicine has become progressively ambiguous and is often used synonymously with clinical testing.

In our opinion, translational medicine encompasses the continuum of activities that extend from the conception of an idea all the way into Phase II/III clinical testing and, ultimately, the development of a tangible product. This itinerary includes multiple and diverse components requiring very different skills and competencies ranging from molecular medicine to pharmacology; from animal testing to clinical trial design; from intellectual property to venture capital.

Translational medicine is therefore the framework needed to ensure the evolution of novel technologies into tangible benefits for patients.

Key Data

Coffee Service and Informal Discussion: 8:15

Debriefing: 8:30

Start Time: 9:00

Wine and Cheese Events: Monday and Wednesday

Dinners: Sunday and Saturday, 20:00

Course Venue

Most of the lectures, case studies and mentoring sessions will be held at the Borgia del Casale, located in the Piazza Duomo in the heart of Ortigia.

Address:
At Borgia del Casale, Via Picherali 10, Stairs B, Interno 4 (off the piazza Duomo) Siracusa.

Rooms dedicated for the conference:
Salotto dei Viaggiatori
Salotto delle Arrti
Alcova
Stanza degli specchi

Lunches and the opening and closing dinner will be held in the Dehor, and the Dammusi.

In the event that you need to contact the venue:
Telephone: +39 0931 22509
Mobile: +39 335 256201 and +39 339 548804

About the Program

You will find in the following pages:

- a brief introduction to Eureka and Translational Medicine
- basic logistical information
- course materials organized by day
- faculty, artists' and participants' bios

This is a living document that will grow and change with you as you move through the course. Because we focus on active participation rather than passive processes, the program will be tailored to your needs and expectations, both the ones pre-defined and those that arise *in situ*. The program materials are organized chronologically. For each session, you will find an abstract as well as its principal learning objectives.
Each day will start at 8:15 with coffee and brief social period, which will segue into the first session of the day (at 8.30 AM). The course is balanced between didactic sessions, interactive discussion, and practical application. Please make opportunities to synthesize the discussions and explore, in a personal context, how the topics covered can be applied to your own work. Course evaluations will be collected at the end of each day.

Eureka Faculty Roster - May 2014

Marco Abbate, B.Sc., M.Sc,
Cpsychol, Acute Frog Consulting, Partner

Salvatore Albani, M.D., Ph.D.,
Professor, Duke-NUS Graduate Medical School, Director, Sing-Health Translational Immunology and Inflammation Centre, UCAN-A Chair

Sylvia Brugman, Ph.D.,
Senior Postdoc, Cell Biology and Immunology group, Wageningen University; E-course developer, Eureka Institute

Roberto Chinello, M.B.A., B.S. Economics,
Acute Frog Consulting,

Dirk Elewaut, M.D., Ph.D.,
Professor of Rheumatology and Immunology; Head, Laboratory for Molecular Immunology and Inflammation; Division of Rheumatology, a EULAR and FOCIS Center of Excellence; Ghent University Hospital

Hans-Georg Eichler, M.D., M.Sc.,
Senior Medical Officer, European Medicines Agency

Wainwright Fishburn, J.D.,
Partner, Cooley Godward Kronish LLP

Patricia Furlong, R.N., B.S., M.S.,
Founding President and Chief Executive Officer, Parent Project Muscular Dystrophy

Carol Gregorio, Ph.D.,
Professor of Cell Biology and Anatomy, and Molecular and Cellular Biology; Member, BIO5 Institute; Director, Molecular Cardiovascular Research

David Hafler, M.D.,
Chief and Chair of Neurology, Yale New Haven Hospital and Yale School of Medicine

Janet Hafler, Ed.D.,
Professor of Pediatrics, Assistant Dean for Educational Scholarship, Yale School of Medicine

Matthias von Herrath, M.D.,
Professor and Member with Tenure at the La Jolla Institute for Allergy and Immunology

Paul Krieg, Ph.D.,
Professor of Cell Biology and Anatomy and Molecular and Cellular Biology, The University of Arizona

Juan Carlos Lopez, Ph.D.,
Head of Academic Relations and Collaborations at Hoffmann-La Roche

Giovanni Mariggi, Ph.D.,
Associate, Index Ventures Life Sciences

Jan Vos van Marken, M.B.A,
Director, UNOVATE (a University Medical Centre Utrecht holding company for service companies)

Andrew Marshall, Ph.D.,
Editor-in-Chief, Nature Biotechnology

Alberto Martini, M.D., Ph,D.
Professor of Pediatrics, Dept of Pediatrics, University of Genoa, Director Pediatria II Reumatologia (EULAR Centre of Excellence in Rheumatology 2008-13), IRCCS G Gaslini, Genoa, Italy

Frank Miedema, Ph.D.,
Dean and Vice Chairman of the Board and professor of Immunology, University Medical Centre Utrecht, the Netherlands

Norman Rosenblum, M.D., FRCPC
Professor of Paediatrics, Canada Research Chair in Developmental Nephrology, and Associate Dean, Physician Scientist Training, University of Toronto

Vicki Seyfert-Margolis, Ph.D.,
Chief Scientific and Strategy Officer, Precision Health Holdings; CEO and Founder, My Own Med

Berent Prakken, M.D., Ph.D.,
Professor of Pediatric Immunology, University Medical Centre Utrecht; Co-Chair, UCAN-U; Chair, EUTRAIN

Khee Chee, Soo, M.D.,
Professor and Senior Vice Dean of Clinical, Academic & Faculty Affairs, Duke-NUS Graduate Medical School, Deputy Group Chief Executive Officer, Research and Education, SingHealth Services

Lucy Wedderburn, M.D., Ph.D.,
Professor, Paediatric Pheumatology, University College London

Eureka Artists-in-Residence

Anna van Schtelen
Brian Goeltzenleuchter

Eureka Observers & Guest:

Sumita Anant, Ph.D.,
Senior Associate Director, Clinical Sciences, Duke-NUS Graduate Medical School
Alison Buchan, BSc., MSc., Ph.D., Professor and Vice-Dean Research and International Relations, University of Toronto
Joseph Ferenbok, Ph.D., Co-Director, Translational Research Program in Health Science, University of Toronto
Eureka Special Observers
Alan Landay, Ph.D., Professor and Chairman, Department of Immunology/Mirobiology, Rush University Mecial Center
Rebecca Ludwig, Ph.D., Education and Training Manager, European Research Infrastructure for translational Medicine – EATRIS
Gerard Pasterkamp, M.D., Professor, Department of Cardiology, University Medical Center, Utrecht

Eureka Principal Organizers

Salvo Albani
Janet Hafler
Juan Carlos Lopez
Jan Vos van Marken
Julia Ong
Berent Prakken
Norm Rosenblum
Vicki Seyfert-Margolis

Introduction e-learning module for Translational Medicine

This year, for the very first time, the Eureka course has started with an online introduction prior to the face-to-face course in Siracusa in May. The course was developed by Eureka Faculty (coordinated by Juan Carlos Lopez) and Sylvia Brugman, a 2010 Eureka alumnus together with Davey van de Heijden and Renee Filius (both at Elevate health). It was made possible thanks to generous support from EUTRAIN and the Child Health program of the UMCU. Elevate Health is an online academy that educates international health professionals, elevating professional knowledge and improving health worldwide. This online e-learning course (e-course) aims to get everyone up to speed with regards to the definition and components of Translational Medicine before the participants arrive at the face to face course in May.

Sunday, May 11th

Coffee
Time: 8:15 - 8:45

Welcome & Introduction
Facilitator: Janet P. Hafler, Ed.D.
Time: 8:45 - 9:45

Mapping Translational Medicine
Presenters: Salvatore Albani, M.D., Ph.D., and Berent Prakken, M.D., Ph.D.
Time: 9:45 - 11:30

Abstract
In this session, the objectives of the course and concepts of translational medicine will be introduced and defined.

Objectives
1. Define the field of translational medicine
2. Analyze the components involved
3. Discuss the challenges of translational medicine

(with in session break)

Group Lunch, 11:30 - 12:30

A Dose of Hope
Presenter: Patricia Furlong, B.S., M.S.N.
Time: 12:30 - 13:30

Abstract
Patients and family members, when faced with a catastrophic diagnosis (rare or otherwise) feel isolated and alone. The dreams and plans for the life they imagined are gone. Parents with sick children feel as if they have failed parenthood, no longer able to 'fix' things or dry every tear. They have few choices and by default, become an advocate. They search the internet, sign up for Google alerts, connect on FB and Twitter. They join registries. They learn a new language and may travel long distances to find physicians with expertise and interdisciplinary care. They start foundations and form virtual biotech companies. They become caregivers, caretakers, pseudo scientists and doctors, investors and partners. They educate family, extended family, school, community and every physician they will ever meet. They learn a new language, drive regulatory science and healthcare policy. They navigate systems and actively campaign for change. They are aggressive, fearless and effective.
They have one single goal – TIME.

Objectives
1. Discuss trajectory of a pediatric rare disease diagnosis
2. Identify opportunities and time points for intervention, support, engagement
3. Discuss the ecosystem of rare diseases and opportunities for partnership between healthcare professionals, researchers, parents/family members and the biopharmaceutical industry

The new collaborative: Big Data without the crowd is just "Big Data"
Presenter: Vicki Seyfert-Margolis, Ph.D.
Time: 13:30 – 14:30

Abstract
We are living in a tsunami of data driven by the ubiquitous access and use of the internet, mobile technologies and the hyper-connectedness of people globally. The term "big data" originated in supercomputing but now touches every aspect of our lives from finance, to advertising, retail and science and health. But is big data technology the problem? Today the capacity to generate, store and manage big data is available and being used routinely. But where is the knowledge from big data? What is keeping big data out of reach? It's not the technology, it's the people. Thousands of patients are seen everyday, but not everyone gets tested or has access to the fruits of big data. Our data remains in silos, desperately needing to be connected and analyzed to gain knowledge. And the challenges of gaining the knowledge from big data requires teams, not just the traditional research team, but teams comprised of many different players in the science and medicine system, including the patients. This session explores the importance of building the team and the knowledge by creating collaborations in new ways that leverage technology and the ability to gather input from a new collective of patients, researcher, clinicians, healthcare practitioners and caregivers to generate new meaningful knowledge.

Objectives
1. Discuss key elements of big data, what is it, how is it collected and how is it being used.
2. Discuss the importance of multi-faceted collaborative teams for managing and analyzing big data.
3. Discuss the use of digital technologies to aid in collecting and analyzing big data through the local and global "crowd".
4. Discuss the importance of the patient perspective to gain true insight for translating big data findings into useful knowledge for health management.

Sunday, May 11th

Intro to Case Studies
Presenter: Janet P. Hafler, Ed.D.
Time: 14:30 - 15:00

Abstract
In this session, the large-group, case study method will be contextualized, and the variety of teaching methods used during the course will be presented.

Objectives
1. Define the learning method
2. Practice critical thinking skills

Break, 15:00 - 15:15

A Case Study: "Sisyphus"
Facilitator: Norman Rosenblum, M.D.
Written by: Salvatore Albani, M.D., Ph.D. and Jessica Colomb, B.A.
Time: 15:15 - 16:15

Abstract
"Sisyphus" is based on a real case about the development of a novel immunotherapeutic strategy. It focuses on compounds designed specifically for humans. Sisyphus addresses typical problems in proof-of-concept studies, development and regulation. This case also prevents in-congruities in animal models of disease versus human application.

Objectives
1. Explore strategies for lead identification
2. Explore strategies for chemistry, manufacturing and controls (CMC) studies (funding and conduct)
3. Explore strategies for safety data in untraditional models

Mentoring Session I
Time: 16:15 - 17:00

Abstract and Goals
As part of the course, participants will present a dilemma they are currently facing to a small group of peers. This group will be mentored by faculty. Fellow course participants will act as a consultation group. The objective is to advance personal learning while practicing and improving approaches to, and organization of, problem solving. Reflections using practical real-world problems will anchor the concepts raised in the didactic portion of the program.

Day 1 Evaluations Collected

Social Program (Sunday)

Tour of the Borgia del Casale and Opening Dinner

20:00

Please join us to celebrate the 6th Annual International Certificate Program in Translational Medicine. Appetizers precede the dinner. Both will be served at the Borgia del Casale.

Monday, May 12th

Pick Up Time, 8:30 sharp in Piazza Archimede

Team Building Day

Facilitators: Marco Abbate, B.Sc., M.Sc, Cpsychol, and Bob Chinello, M.B.A., B.S.
Logistical Note: Participants will meet in the Piazza Archimedes at 8:30 am EXACTLY on Monday morning. Busses will be waiting to transport participants to the beach where the team building exercise is being held.
Time: 8:30

Abstract

The team building exercise will be led by Bob and Marco, of Acute Frog Consulting and will be comprised of a series of group activities to help the participants to make a better use of their teams by understanding team dynamics and the "social ingredients" of effective interaction.

Objectives

Dig into some important issues related to "being in a team"
1. When does a "loose affiliation of individuals" become a team?
2. Group decision-making: relationship, negotiation, conflict and feedback: join the party!
3. Team dynamics: communication, trust, diversity, alignment, common objectives

Social Program (Monday)

Wine and Cheese
20:00 - 21:15

Tuesday, May 13th

Coffee
Time: 8:15 - 8:30

Debriefing
Time: 8:30 - 9.00

Teaching and Learning
Presenter: Janet P. Hafler, Ed.D.
Time: 9:00 - 10:00

Abstract
In this session, the team building exercise from the previous day will be explored, and how case based teaching in integrated into the curriculum.

Objectives
1. Define what constitutes a team
2. Discuss principles of effective group interaction
3. Discuss networks and their influence on career and science

Unfolding Case Study 1: The Magic Bullet
Written by: Vicki Seyfert-Margolis, Ph.D.
Time: 10:00 - 11:30

Abstract
This case examines the full translational tightrope of a targeted therapy, from lead identification to Phase
II and III clinical trials. Participants will work in depth with the case in a small group setting over three separate sessions.

Recommended reading will be provided
Slamon DJ et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001 Mar 15;344(11):783-92. PMID: 11248153. Available at http://www.nejm.org/doi/full/10.1056/NEJM200103153441101

Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer, J Clin Oncol. 2009 Dec 1;27(34):5838-47. Epub 2009 Nov 2. Review. PMID: 19884552

Objectives
Through this case, participants will grapple with the development of a therapy intended for a targeted sub-population, and explore the issues arising in the post-market phase. In addition, participants will discuss and determine research and business strategies necessary to "translate" a potential therapeutic, and co-develop its companion biomarker. Parallel concepts of collaboration and team will also be explored.

Group Lunch, 11:30 - 12:30

The Concept of druggability: Challenges and Opportunities
Presenter: Salvatore Albani, M.D., Ph.D.
Time: 12:30 - 13:30

Abstract
This conversation will address the general principles inspiring the "druggability" of a compound, technology or process. In other words, what are the key factors influencing the evolution of a scientific discovery or concept through the translational gradient to answer an unmet medical need. A lot of science is outstanding, but not all of it is "druggable".

Objectives
1. Highlight the principles guiding movement from initial investigations into “advanced” studies
2. Discuss designing and managing clinical trials, including data management and interpretation
3. Explore the intersection of interests between key stakeholders (e.g. patients, regulators and business)

Tuesday, May 13th cont.

Pre-Market Medical Product Development

Presenters: Vicki Seyfert-Margolis, Ph.D.; and Hans-Georg Eichler, M.D.
Time: 13:30 - 14:30

Abstract

A background on the latest trends in pre-market product development including biomarkers, diagnostics, devices, drugs and biologics will be discussed with respect to the applied science of product development needed to move more innovative products to the market for patients who need them. Various aspects involved in the science needed to improve product development, from pre-clinical to clinical trials will be described as well as the latest policies under discussion in the United States and Europe.

Objectives

1. Discuss the latest trends, gaps and opportunities in the applied science of product development and evaluation (regulatory science).
2. Describe the stakeholders, priorities and up to date efforts ongoing in regulatory science.
3. Examine the various policy discussions surrounding pre-market product development from discovery to market launch, including funding, regulatory, reimbursement, and other considerations.

Break, 14:30 - 14:45

Modeling diseases and therapies in experimental systems

Presenters: Norman Rosenblum, M.D.
Time: 14:45 - 15:45

Abstract

Animal models are commonly used to model human diseases. But how reliable are these models? How does the researcher decide? Participants will analyze dilemmas researchers can face while working with animal models.

Objectives

1. Discuss when and why to use animal models
2. Examine how to use animal models
3. Explore the differences between animal models and human diseases

From Mountains to Molehills: Transforming Basic Research into Leads s

Presenter: Paul Krieg, Ph.D.
Time: 15:45 - 16:45

Abstract

Basic molecular research generates interesting data and concepts. While conducting successful and insightful experimentation can be rewarding, it is only the gestational step of translational research. In this session, participants will discuss how to evaluate basic research discoveries for leads and give examples of successful basic science studies leading to clinical insights. This session will also examine the TM itinerary in relation to the respective roles of academia, IO, patents and technology transfer.

Objectives

1. dentify what a lead is and its key elements
   Identify strategies for evaluating basic molecular science for translational potential
2. Discuss the next steps once a lead is identified
3. Explore the pathway of IP development within an institution.

Mentoring Session II

Time: 16:45 - 18:10

Abstract and Goals

As part of the course, participants will present a dilemma they are currently facing to a small group of peers. This group will be mentored by faculty. Fellow course participants will act as a consultation group. The objective is to advance personal learning while practicing and improving approaches to, and organization of, problem solving. Reflections using practical real-world problems will anchor the concepts raised in the didactic portion of the program.

Day 3 Evaluations Collected

Wednesday, May 14th

Coffee
Time: 8:15 - 8:30

Debriefing
Time: 8:30 - 9:00

Presentation Workshop Primer
Presenter: Janet P. Hafler, Ed.D.
Time: 9:00 - 9:15

Abstract
The design of the presentation workshop will be introduced. The workshop will focus on content, form, audience assessment and delivery.

Presenting Preparation and Workshop
Presenters: Salvatore Albani, M.D., PhD.; Carol Gregorio, Ph.D.; Paul Krieg, Ph.D.; Juan Carlos Lopez, Ph.D.; Jan Vos van Marken, M.B.A.; Berent Prakken, M.D., Ph.D.; Norman Rosenblum, M.D.; Vicki Seyfert-Margolis
Time: 9:15 - 12:00

Abstract
Participants will be given a 5 minutes presentation. Peers and faculty will critique the presentation and the presenter will self-evaluate.

Objectives
1. Evaluate the best methods for delivering a message
2. Explore strengths and areas of improvement in your personal presentation style
3. Develop presentation/communication skills

Group Lunch, 12:00 - 13:00

Unfolding Case Study 2 - The Magic Bullet (continued)
Written by: Vicki Seyfert-Margolis, Ph.D.
Time: 13:00 - 14:00

Current thinking on clinical trial design/co-development
Presenters: Vicki Seyfert-Margolis, Ph.D. Hans-Georg Eichler, M.D.,
Time: 14:00 - 15:00

Abstract
Predictive markers, toxicology models, and tools to help shape intelligent drug design and diagnostic development will be explored.

Objectives
1. Identify state of art technologies for predicting toxicology and efficacy
2. Discuss use of the above to optimize the development of new therapies
3. Explore principles of intelligent design of drug development

Break, 15:00 - 15:15

Navigating Late-Stage Clinical Development
Presenter: Hans-Georg Eichler, M.D.
Time: 15:15 - 16:15

Abstract
A well-executed translational medicine program will bring a novel therapy through proof-of-concept to beginning Phase 3 trials. Successful navigation of latestage development requires careful coordination of teams with proficiency in multiple key scientific disciplines as well as regulatory expertise.

Objectives
1. Discuss milestone regulatory interactions that take place in late-stage development.
2. Identify various ways that biomarkers can aid clinical development.
3. Identify changes contributing to growing interest in orphan diseases on the part of biotechnology companies and big Pharma.

Wednesday, May 14th cont.

The Mysteries of Communication

Presenters: Juan Carlos Lopez, Ph.D. and D. Hafler M.D., Ph.D.
Time: 16:15 - 17:15

Abstract

The research is complete. The data have been collected and analyzed. But this is no time to rest. The paper has to be written. Publication in a peer-reviewed journal is almost an automatic requirement for a researcher to be able to move a concept into more advanced stages of development. This session will explore the publication process from an editor's perspective, and also how this ties into good research practices.

Objectives

1. Define the key elements to include in a paper
2. Discuss the most common mistakes to avoid
3. Discuss how to create a publication strategy

"Speed Dating", Session 1

Time: 17:15 - 18:30

Abstract and Objectives

"Speed dating" provides the opportunity for participants to have a series of one-on-one discussions with individual faculty for 10 minutes each. Topics are the participant's choice. Please consult the faculty biographies at the end of this program prior to completing the signup sheet, which will be available on Wednesday and Thursday through lunch.

Day 4 Evaluations Collected

Sicilian Delicacies

The title for the "Gastronomic Capital" of Italy is certainly a matter for debate. While some would claim it to be in the Northern regions of the country (specifically Bologna), the South is rich with fresh delicacies. As an island, it makes sense that fish would rank among these fine foods. Bluefin tuna is native of Sicilian waters and sought throughout the world, especially Japan. Fishing techniques date back well over a millennium, with some traceable to Arab rule, and others suspected to be vestiges from the Carthaginian period. Tonnarotti (Italian for tuna fisherman), might recommend a simple breaded tuna steak, while others could tout the finer qualities of "purpetti" (tuna croquettes), or "salsiccia di tonno" (tuna sausage), or even tuna stew. However, one cannot live on fish alone (arguably). Arabic influences transcends savory dishes, and inspires the sweet. Honey, almonds, and sesame seeds are all linked with the Arabic era in Sicily. They are also the main ingredients for sweets in Siracusa. The "giuggiulena" is a perfect example. Giuggiulena is a hard candy made from exactly those three ingredients. Pistachios, ricotta cheese and chocolate also grace many recipes. Consider the "cassata siracusana" with ricotta cheese and chocolate, or perhaps save your calories for authentic and irreproducible Sicilian cannoli. Since we'll be in Siracusa during the Santa Lucia festival, one might try a "cuccìa", made with ricotta cheese and candied squash and fruit. Granita (an icy concoction with almond milk) is paradise on a hot summer day. After all this eating, you might be thirsty. One thing to try (aside from granita) is Nero d'Avola. The origin of the varietal is unknown, and has thus far only been found in Sicily. A sweeter palate will revel in the wine described by Homer and Hesiod: Moscato di Siracusa, which is rumored to be oldest wine in Italy. Whatever your preference, Siracusa is sure to have something unique and delectable for you.

Social Program (Wednesday)

Wine and Cheese
Translational Creativity - Introduction
Facilitators: Anna van Suchtelen and Brian Goeltzenleuchter
20:00 - 21:00

Abstract:
Conventional models of creativity, as typified by artistic fields, presume a singular author sharing a creative object with a passive audience. This introduction to Translational Creativity will outline two alternative approaches: One is a collaborative approach in which creativity is open-ended and co-produced; the other is an individual approach in which creativity is facilitated by a loss of self-awareness and an absence of critical thought.

Effective presenting format

A. Start with a brief statement of the goal to be addressed in your presentation and indicate who you consider to be the target audience.

B. Present for up to five minutes. Your colleagues will participate as the audience and the presentation will be videotaped.

C. 1) You, the presenter, will then view the videotape on your own and, as it plays and for a short time after, develop a list of strengths and suggestions for personal improvement.
2) While the presenter views the tape, the "audience" of colleagues discusses the strengths of the presentation and suggestions for improvement. Suggestions should
- Deal with behavior, not with the person.
- Focus on strengths as much as possible.

D. The presenter and the audience reconvene, each providing feedback on strengths and suggestions. The purpose of this discussion is to:
- allow for self-reflection on the part of the presenter and feedback in the context of suggestions for future teaching.
- define and authenticate issues in teaching.
- provide an occasion for others to help if appropriate.



references: Hewson, MG, Little ML. Giving feedback in medical educaiton: verifaction of recommended techniques. J Gen Intern Med. 1988;13(2):111-116.

The Presentation Workshop Observation Guide

Process

1. How does the presentation begin?
   - How does the presenter capture attention and promote curiosity?
   - How is the overview presented?

2. Is the information presented in a well organized manner?

3. Presentation: Is the delivery paced to the audience's capacity to follow?
   - Does the presenter avoid reading notes?
   - Does the presenter show any distracting mannerisms?
   - Did the presentation start and end on time?

4. How does the presenter promote active participation? Does he/she
   - use movement?
   - make eye contact with the audience?
   - use aids?
   - ask questions that prompt reflection or response?
   - use buzz groups, voting or brainstorming?
   - problem solve?

5. How does the presentation conclude?
   - Is there a review?
   - Are there follow-up tasks?
   - Is there an evaluation (the one-minute paper)?

6. How is learning assessed?

Content

1. Is the content accurate?

2. Does the presenter show a relationship between theory and practice?

3. Is the level of the material appropriate to the audience?

4. Was the presentation complete?

The Presentation Workshop

Feedback Tips



Definition

The process of giving data back to the participant for the purpose of bringing about change.

Feedback involves responding specifically to an event or occurrence, whether that event be good or bad. Positive and negative feedback should be distinguished from complimenting and criticizing.

Evaluation is an assessment of a learner's achievement and/or performance.

1. Feedback should be undertaken with the observer and participant working as allies with common goals. Begin by discussing respective expectations.
2. Feedback should be descriptive rather than evaluative.
3. Feedback should deal with specific events, rather than generalizations.
4. Feedback should be well-timed, and expected, in close proximity to the event, but not when — the recipient is postcall or angry about the issue; facts are missing; or both sides of the situation have not been explored.
5. Feedback should be based on first-hand data.
6. Feedback should be focused on behaviors that are amenable to change.
7. Feedback should involve sharing of information, rather than giving advice, leaving the receiver free to decide for themselves in accordance with their own goals and needs.
8. Feedback can be structured to include subjective data, as long as it is clearly labeled as such.
9. Feedback should be checked to insure clear communication by having the receiver try to rephrase the feedback.
10. Feedback should be followed by attention to the consequences of feedback.

Taking the Plunge

1. Be clear about the purpose of the feedback session.
2. Get the receiver's perspective as to how things are going.
3. The sandwich technique (i.e., good / bad / good) isn't always reliable.
4. Ask the recipient to offer solutions.
5. Develop solutions to the problem, and a plan to improve the situation.

Thursday, May 15th

Coffee
Time: 8:15 - 8:30

Debriefing
Time: 8:30 - 9:00

Translational Creativity Workshop
Artists/Facilitators: Anna van Suchtelen and
Brian Goeltzenleuchter
Time: 9:00 - 11:30

Abstract
Paintings for Drowning Men: A workshop on translational creativity is a participatory art workshop. Artists Anna van Suchtelen and Brian Goeltzenleuchter will lead a workshop in which participants will lose themselves in creative "tasks", shifting between the comical, the philosophical, and the therapeutic. At the end of the workshop students should possess techniques to facilitate the creative process - from innovation through development and actualization. Students will work alone and in small groups. Each activity will be followed by a period of reflection in which students are encouraged to process the activity and make notes on how to integrate creative techniques in their lives.

NOTE: Prior to the workshop students are required to watch the video, When to Throw a Painting to a Drowning Man, which was produced for the Eureka 2011 Program. The video can be streamed here: http://vimeo.com/47049893

Group Lunch, 11:30 - 12:30

Clinician and biomedical scientists - do they speak the same language?
Presenter: Khee Chee, Soo, M.D.
Time: 12:30 - 13:30

Abstract
There is a spectrum of biomedical research that extends from the bench studying basic biological processes , to the bedside where clinical observations, research and trials are undertaken, to health systems and services where implementation of initiatives and behaviors are studied. We assume that biomedical scientists and clinicians and health policy makers are fluent communicating to one another . Often this is not the case and as a consequence opportunities for robust collaborations are missed and sometimes worse misunderstandings arise between different groups of researchers. To be discussed in the presentation are measures to align not just the language but priorities and initiatives of biomedical research.

Evolving Models of Science: is the principle investigator model dead?
An interview with David Hafler, M.D.
Facilitator: Vicki Seyfert-Margolis, Ph.D.
Time: 13:30 - 14:15

Thursday, May 15th cont.

Speed Dating II
Time: 14:30 - 15:30

Abstract and Objectives
"Speed dating II" provides another opportunity for participants to have a series of one-on-one discussions with individual faculty for 10 minutes each. Topics are the participant's choice. Please consult the faculty biographies at the end of this program prior to completing the signup sheet, which will be available on Wednesday and Thursday through lunch.

Unfolding Case Study 3 - The Magic Bullet (continued)
Written by: Vicki Seyfert-Margolis, Ph.D.
Time: 15:30 - 16:15

Science 3.0
Presenter: Frank Miedema, Ph.D.
Time: 16:15 - 17:15

Abstract
When people think of a scientist, they often think of someone who has his or her head in the clouds, motivated by an entirely untainted desire for the pursuit of knowledge and truth. In this presentation Frank Miedema will cast aside these beliefs about scientists as needlessly naïve, and instead suggest that we rebuild our idea of the sciences, particularly the life sciences, with today's economic reality in mind.

Objectives
1. Understand the impact of external forces on Science as it relates to translational Medicine.
2. Develop awareness of the way science shapes both economic and social progress in modern society.
3. Realize how increasing pressure to solve real-world problems has forced scientists out of the ivory tower and into the corporate world.

Day 5 Evaluations Collected

Friday, May 16th

Coffee
Time: 8:15 - 8:30

Debriefing
Time: 8:30 - 9:00

A Stroll in the Valley of Death: Strategies for Developing a Start-up in the Current Climate
Presenters: Salvatore Albani, M.D., Ph.D.; Wain Fishburn,J.D.; Juan Carlos Lopez, Ph.D.
Time: 9:00 - 10:30

Abstract
The "Valley of Death" is a term typically used to describe the vast expanse between an idea and its delivery to patients and the market. The valley is cloaked by the fog of unawareness and swept by the winds of uncertainty. Many dangers lurk in it. We will discuss the various challenges which have to be overcome, including but not limited to funding in the current climate. We will suggest strategies to maximize the chances of success. Our objective is to disperse the fog and provide awareness of the process.

Objectives
1. Identify the elements leading to the formation of a company as a development vehicle for a translational idea
2. Describe the current funding process as well as funding policies and their impact
3. Examine the challenges start-ups encounter in developing an idea into a product tangibly benefitting patients

So you want to spend other people's money?
Presenters: Juan Carlos Lopez, Ph.D., Giovanni Mariggi, Ph.D. Andrew Marshall, Ph.D.;
Time: 10:30 - 11:30

Abstract
The most arduous part of translating a project into a product is convincing other people to provide you with financing support for your development plan. The effort and challenge of obtaining a financing commitment from investors is often underestimated by entrepreneurial scientists. Nowadays, several public and private funding sources can help get your company off the ground, at least at the early stage. To help maximize your chances of finding the cash needed it is important to understand the early stage financing landscape, the audience you are pitching to and their objectives. The classic path after seed investment involves a financing round from venture capitalists, professional investors usually with domain expertise, but the number of VC firms that operate in the biomedical space has decreased over the past decade. This means more competition and fewer ears for your pitch. Talking with investors will allow you to gauge whether your venture is perceived to have a chance of succeeding and if there is a place for your product in the market. You will also want to assess whether you and a potential investor are a fit as you will undoubtedly go through difficult times and the relationship will be tested. The strength (or weakness) of this relationship can make or break your company. We will provide a window to the venture capital-centric view of the financing process to help you focus on the important aspects whilst engaging with your investors.

Objectives
1 Learn about the different sources of funding and the stage at which each should be sought
2 Understand your audience: know what a venture capitalist is looking for and what their objectives are
3 Build relationships well before you will be looking for funding
4 Choose your investors and pitch accordingly to common grounds between your plans and their expectations

Group Lunch, 11:30 – 12:30

Siracusa

Some 2,700 years ago, one of the first Greek settlers dubbed this area "Sirako". This was in reference to the surrounding salt marshes, beautiful areas dense with sensitive and highly specialized vegetation. Its strategic location and saavy inhabitants helped make Siracusa one of the most powerful city-states in all of Magna Grecia. Cicero called it "the most beautiful of them all". Ruling factions have changed over time, with the Romans, Byzantines, Arabs, Normans and Swabians all fighting for supremacy in the region. Sicily (and Siracusa) has survived each invasion, and absorbed some important influences evident today. For example, May is the opening month of the Greek Theatre, a premier theatrical event in all of Italy. Architecture further infuses the bones of the city, doric and ionic, baroque and roccoco. And art (high and low, old and new) adorns the cityscape and enriches its museums.

Siracusa is not buried in its past, however. The city's heartbeat is strong with the song of the dolce vita; "ragazzi" enjoy the night life sitting at an open-air coffee-shops, or dancing in one of the many clubs that are concentrated in the area between Piazza Archimede, Piazza Duomo, the Aretusa Fountain and the Alfeo Promenade.

Friday, May 16th cont.

The discovery-translational pathway: Is this right for me?

Moderator: Wain Fishburn, J.D.
Panelists: Vicki Seyfert-Margolis; Ph.D Salvatore Albani, M.D., Ph.D; David Hafler, M.D.
Time: 12:30 - 13:30

Objective

To highlight what it takes to leave the traditional lane within academia or industry... what are the characteristics of people who do this successfully, what are the risks, what are the rewards ...

Grant Writing Workshop

Facilitators: Carol Gregorio, Ph.D., Paul Krieg, Ph.D. and Norman Rosenblum, M.D.

Abstract

Participants will focus on elements of persuasive grant writing using samples of their own grant summary pages as a foundation.

Objectives

1. Explore effect structures (e.g. abstract flow)
2. Examine content for message clarity and delivery
3. Learn self-assessment strategies for written work

Mentoring Session III

Time: 15:00 - 16:00

Abstract and Objectives

See session 1 (Sunday) for abstract and objectives

Emerging Models in Translational Medicine partnerships and entrepreneurship

Presenters: Vicki Seyfert-Margolis, Ph.D., Matthias von Herrath, M.D.
Time: 16:00 - 17:00

Abstract

Bringing an idea from discovery to the clinic always was a team effort. Formal recognition of this by academia, non-profits, governments and industry has now resulted in the formation of many new forms of public-private partnerships to advance translational medicine. From large, broad, clinical research partnerships like the Innovative Medicines Initiative in the European Union, to very focused specific partnerships like that between the US Cystic Fibrosis Foundation and Pfizer, these models are here to stay.

Objectives

1. Discuss various partnership models and the roles that each partner brings.
2. Discuss examples of several different types of partnerships at work today.
3. Discuss expectations of partners in these relationships.

Translational Creativity

Artists/Facilitators:: Anna van Suchtelen and Brian Goelt-zenleuchter
Time: 17:00 - 17:30

Abstract

Highlights from the Translational Creativity workshop will be discussed.

Day 6 Evaluations Collected

Saturday, May 17th

Coffee
Time: 8:15 - 8:30

Debriefing
Time: 8:30 - 9:00

Small Piece, Big Pie
Presenters: Dirk Elewaut, M.D., Ph.D., Berent Prakken, M.D., Ph.D.
Time 9:00 - 10:15

Abstract
This interactive session will discuss the pitfalls of collaborative research in translational medicine. Various partners (academic institutions, industry, regulatory authorities, etc) are implicated when pursuing research in this area.

Objectives
1. Identify differences in approaching collaborative research with different organizations (academia versus industry)
2. Discuss the issue of intellectual property and confidentiality
3. Identify strategies to tackle obstacles in collaborative research

The "I" / "We" Dilemma, or Is Cooperation an Ingredient to My Success
Facilitators: Berent Prakken, M.D., Ph.D.; Norman Rosenblum, M.D.,
Time: 10:15 - 11:30

Abstract
This interactive seminar will explore the issue of individual achievement and cooperation in the context of translational research. Methods to enhance cooperation will be explored. The limits of the 'cooperation model' will be highlighted and 'conflict-resolution' theory will be harnessed to propose a method by which investigators can achieve a higher state of cooperation and greater achievement in research.

Objectives
Highlight tensions between individual and team-based achievement in research.
Understand limits of the conventional model of cooperation.
Explore use of conflict-resolution theory to reach a higher stage of cooperation and achievement in research.

Group Lunch, 11:30 - 12:30

A Case Study: "Sisyphus"
Facilitator: Norman Rosenblum, M.D.
Time: 12:30 – 14:00

Abstract
This case study is based on epitope-specific immunotherapy and focuses on compounds designed specifically for humans. Sisyphus addresses typical problems in proof-of-concept, development and regulation. This case also includes the incongruities in animal models of disease versus human application.

Objectives
Explore strategies for lead identification
Explore strategies for chemistry, manufacturing and controls (CMC) studies (funding and conduct)
Explore strategies for safety data in untraditional models

Day 7 Evaluations & Overall Evaluation Collected

Course Evaluations
This interactive session will be guided by participants.
Faculty will not be present.
Time: 14:00 - end of session

Social Program (Saturday)

20:00 closing dinner:

After a week of hard work, creativity and fun please join us for an amazing dinner with enticing wines. Dinner will be served at the Borgia del Casale in the historical suite of Regina Lucia.

The birth of Translational Creativity

In 2011, the time was ripe for the Eureka Institute for Translational Medicine to add Art into their program: Eureka Translational Creativity was born. Since May 2011, Eureka has created work space for artists during the Siracusan course to collaborate with and reflect on the field of Translational Science.

The first invited artists were Brian Goeltzenleuchter and Anna van Suchtelen. In 2011, they were in residence in Sicily, which resulted in the film When to Throw a Painting to a Drowning Man, released in 2012.

2011-2012: When to Throw a Painting to a Drowning Man

The project

When to Throw a Painting to a Drowning Man is an artist-made self-help video that shows how creativity can be useful to anyone.

The video offers parables and exercises that evoke the structure of a self-help book. It celebrates the transcendent nature of creativity, examining its potential as a skill and tool for problem solving, critical thinking, networking, and team building.

Artists Brian Goeltzenleuchter and Anna van Suchtelen were invited by the Eureka Institute for Translational Medicine to participate in its international workshop designed to train a new class of translational researcher. The artists developed this video to highlight the false dilemma of considering art and science as binary opposites. Focusing, instead, on the commonality of innovation, the artists produced this video for an audience of innovators who strive to come to terms with the uncertainty that accompanies working collaboratively and across disciplinary borders.

Eureka Translational Creativity

Translational Creativity 2013: Kate Breakey

In 2013 photographer Kate Breakey was invited. She was in residence in Siracusa during the 2013 course and created the work: The Syracusa Still Life. She collaborated with the participants to create an artwork, using produce from local Sicilian market as raw materials and classical Italian still life painting as inspiration to construct a still life tableau. The objective was to integrate many small parts into a larger whole that becomes more than the sum of those parts.

The artist

Kate Breakey is internationally known for her large-scale, richly hand-colored photographs including her series of luminous portraits of birds, flowers and animals. Since 1980 her work has appeared in more than 85 one-person exhibitions and in over 50 group exhibitions. Her work is held in many public institutions. A native of South Australia, Kate moved to Austin, Texas in 1988. She completed a Master of Fine Art degree at the University of Texas in 1991 where she also taught photography in the Department of Art and Art History until 1997. In 1999, she moved to Tucson, Arizona. Her 4th book, a collection of photograms, entitled 'Las Sombras / The Shadows' was publish in 2012.

Syracusa Still Life (2013)

ADMINISTRATIVE FACULTY BIOGRAPHY

Julia Ong, B.Com.

Julia is the Manager of SingHealth Duke-NUS Paediatrics Academic Clinical Program (Paediatrics ACP) and was seconded, half headcount to Eureka Institute as the Executive Manager helping Professor Salvatore Albani.

Julia has 24 years of vast experience as an administrator and of which, 12 years were in healthcare. Julia joined KK Women's and Children's Hospital in 2006 working alongside the Head of Women Psychiatric Service under the Division of Medicine, setting up the service to a department in 2011. She was transferred in November 2011 to lead the setup of Paediatrics ACP, supporting the two pillars of Research and Education in Academic Medicine.

Her work scope has been very broad base covering organising events for public, create awareness, co-edited a personal sharing book on Postnatal Depression, data managements, budgets, lead education and research team to organise medical education activities for doctors and research operational/statistical support in Paediatrics ACP.

She was seconded half headcount to Eureka Institute as Executive Manager in October 2013, and is honoured for the opportunity.

EUREKA
Institute

FACULTY DISCLOSURES

FACULTY BIOGRAPHIES

EUREKA INSTITUTE™
for translational medicine

FACULTY DISCLOSURES

Nothing to disclose

Marco Abbate, B.Sc., M.Sc,
Salvatore Albani, M.D., Ph.D.,
Sumita Anant, Ph.D.
Sylvia Brugman, Ph.D.,
Roberto Chinello, M.B.A., B.S. Economics,
Dirk Elewaut, M.D., Ph.D.,
Hans-Georg Eichler, M.D., M.Sc.,
Wainwright Fishburn, J.D.,
Patricia Furlong, R.N., B.S., M.S.,
Carol Gregorio, Ph.D.,
Janet Hafler, Ed.D.,
Matthias von Herrath, M.D.,
Giovanni Mariggi, Ph.D.,
Jan Vos van Marken, M.B.A,
Alberto Martini, M.D., Ph.D.
Frank Miedema, Ph.D.,
Norm Rosenblum, M.D.,
Maria Grazia Roncarolo, M.D., Ph.D.,
Khee Chee, Soo, M.D.,
Lucy Wedderburn, M.D., Ph.D.,

Disclosures

David Hafler, M.D.
discloses an affiliation with Allozyne Inc., Bayer Yakuhin, Ltd, Genzyme, McKinsey and Company, NKT Therapeutics, Novartis Pharmaceuticals, Questcor, Teva Neuroscience, Pfizer, Sage Therapeutics, the Cleveland Clinic Foundation, EMD Sorono, Mylan Pharmaceuticals and Vitae Pharmaceuticals as a consultant/Scientific Advisory Board.

Juan Carlos Lopez, Ph.D.,
discloses an affiliation with Hoffmann-La Roche as an employee.

Paul Krieg, Ph.D.
discloses an affiliation with Angionics as a major stock holder.

Vicki Seyfert-Margolis, Ph.D.,
discloses an affiliation with MyOwnMed, Inc, Apomax,Inc and Seraxis, Inc as a major stock holder.

Berent Prakken, M.D., Ph.D.,
discloses an affiliation with FP7EU program, Dutch Arthritis Foundation and NWO for grant/research support, consultancy/scientific advisory board Danone Research, Novo Nordisk, ProtAb and Amgen.

Disclosure not available at time of printing

Andrew Marshall, Ph.D.

FACULTY BIOGRAPHIES

Marco Abbate BSc, MSc, Cpsychol

I am a Chartered Occupational Psychologist in the UK and in Italy. My ten years' experiences as a Chartered Occupational Psychologist in several fields and nearly eight years in coaching and recruitment have allowed me to acquire a round profile. I work with International SME (Small and Medium Enterprises) on projects related to Organisational Development, Coaching, Recruitment and Training. The numerous international projects followed in the UK, Italy, Germany, Spain and China have taught me and continue to teach me that living and working together in an Organisation is an issue that scares both management and their team, and is and will be a great challenge for the organisations and those working within.

Please find more about me: uk.linkedin.com/in/marcoabbate/

My model is based on the psychodrama. It is a dramatic action to examine problems or issues raised by an individual. Using experiential methods, sociometry, role theory, and group dynamics, Psychodrama facilitates insight, personal growth, and integration on cognitive, affective, and behavioural levels. It clarifies issues, increases physical and emotional well being, enhances learning and develops new skills.

marco.abbate@ma-talent.net

FACULTY BIOGRAPHIES

Salvatore Albani, M.D., Ph.D.

My fundamental research interest is in understanding human immunity and contributing the knowledge to therapeutic and diagnostic advancements. I have developed several innovative approaches in the area of induction and maintenance of immune tolerance in humans, being responsible for the whole translational process from idea to the conclusion of a Phase II clinical trial in autoimmune inflammatory diseases, which have a large impact on society and individuals. I have been responsible for conception and execution of each of the stages of this complex itinerary, which spans a wide and diverse gradient of technologies and challenges.

These include molecular immunology, lead identification and validation, intellectual property, CMC (Chemistry, Manufacturing and Controls), IND (Investigational New Drug filings), trial design, data management and analysis, interfacing with Venture Capital and Pharma, leading complex groups in a multi-center setting, etc. The technology platform has applications in diseases that could benefit from a restoration of immune tolerance. This translational research itinerary has been the original backbone of my career, as witnessed by a rich publication trail (among others Nature Medicine, Lancet, JCI, PNAS, Nature Rheumatology, A&R, ARD, etc) and by approximately 100 patents.

Development of high throughput technology platforms is also part of my scientific career. These platforms aim to provide tools for knowledge-based diagnostic and therapeutic decisions (various papers and patents under review).

In addition, I have developed a technology for the identification and manipulation ex vivo of antigen- specific T cells. This technology, named T cell capture, is based on entirely artificial antigen presenting cells. It has applications in immunotherapy of cancer and treatment of infections in an immunocompromised host (Nature Medicine, JI. Blood, A&R, Haematologica, various patents). Combined, these approaches span both ways across the gradient of Translational Medicine, which is evidence of and underscores my dedication to this field.

In my role as an educator, it has been my privilege to mentor many talented individuals, and to provide the right challenges and learning opportunities to help them grow and advance. I seek to expand this even further by helping to create and nurture the next generation of translational scientists. An important step is cultivating in translational professionals the necessary awareness, knowledge and experience to contribute significantly to the advancement of the field.

FACULTY BIOGRAPHIES

Sylvia Brugman, Ph.D.

Sylvia Brugman is a senior postdoc at the Cell Biology and Immunology group, at Wageningen University where she investigates the intestinal mucosal immune system in health and disease. She investigates microbial composition and immune regulation in the zebrafish gut, and has developed a model for zebrafish enterocolitis. Her current research focuses on innate and adaptive immune mechanisms controlling the response towards microbial and dietary antigens in the intestines and respiratory tract. Sylvia is an alumnus of the Eureka Certificate Program for Translational Medicine (2010). From 2013 she is appointed as e-course developer for the Eureka Institute and together with Elevate Health she developed the introductory course.

FACULTY BIOGRAPHIES

Roberto Chinello, M.B.A.,B.S. Economics

I am an experienced consultant with over 20 years experience, with multiple industry exposure, focused on delivery project, change management and organizational development. My passion is about creating strategic foresight and innovative leadership in business and new venture environments, to help anticipate and evaluate future uncertainty, respond to emerging opportunities, and innovate and transform to exploit them. I strongly believe that “people” is what makes the difference at the end of the game.

Please find me in http://it.linkedin.com/in/robertochinello
Composing music means dealing with silence, the thing that happens 'between' sounds. For me, consulting means dealing with what happens 'between' the parts of the organization, the processes, behaviors and decisions. I have learned to listen and actively use silence to understand that there is always a good reason for what I observe. Listening is what makes change possible in organizations, because when we understand what such organizations are we can work to improve their resources, i.e. the things that an organization knows and knows how to do. Jaco Pastorius, an electric jazz bassist I love, said "Keep your mind open, listen to everything that's being played", and I think of this as I watch my children grow and when I play the bass. I have worked in Europe, the USA and Japan. And I have tried to always keep my ears open.

roberto.chinello@acutefrog.com

FACULTY BIOGRAPHIES

Hans-Georg Eichler, M.D., M.Sc.

Hans-Georg Eichler, M.D., M.Sc., is the Senior Medical Officer at the European Medicines Agency in London, United Kingdom, where he is responsible for coordinating activities between the Agency's scientific committees and giving advice on scientific and public health issues. From January until December 2011, Dr. Eichler was the Robert E. Wilhelm fellow at the Massachusetts Institute of Technology's (MIT) Center for International Studies, participating in a joint research project under the MIT's NEWDIGS initiative. He divided his time between the MIT and the EMA in London.

Prior to joining the European Medicines Agency, Dr. Eichler was at the Medical University of Vienna in Austria for 15 years. He was vice-rector for Research and International Relations since 2003, and professor and chair of the Department of Clinical Pharmacology since 1992. His other previous positions include president of the Vienna School of Clinical Research and co-chair of the Committee on Reimbursement of Drugs of the Austrian Social Security Association. His industry experience includes time spent at Ciba-Geigy Research Labs, U.K., and Outcomes Research at Merck & Co., in New Jersey. Dr. Eichler graduated with an M.D. from Vienna University Medical School and a Master of Science degree in Toxicology from the University of Surrey in Guildford, U.K. He trained in internal medicine and clinical pharmacology at the Vienna University Hospital as well as at Stanford University.

Professional Activities, since 2000:
2011 Robert E. Wilhelm Fellow at the Center for International Studies (CIS) at the Massachusetts Institute of Technology (MIT) and the NEWDIGS initiative. Cambridge, Massachusetts, United States of America
2007 - Senior Medical Officer; European Medicines Agency (EMA), London, United Kingdom
2006 - 2007 Austrian Representative, Contact Group at the EC, Innovative Medicines Initiative Strategic Research Agenda
2005 - 2007 Member, Scientific Advice Working Party (SAWP) at the European Medicines Agency
2005 - 2007 Managing Director, Medical University of Vienna International Hospital Operations GmbH
2005 - 2007 Project Director MUV, Prince Court Medical Center, Kuala Lumpur, Malaysia
2003 - 2007 Vice-Rector, Research and International Relations; Medical University of Vienna (MUV), Vienna, Austria
1995 - 2007 Co-Chair, Committee on Reimbursement of Drugs of the Austrian Sick Funds and Social Security Association
1992 - 2007 Professor of Clinical Pharmacology, Medical University of Vienna
2001 - 2006 Member, Steering Committee, European-Developing Countries Clinical Trials Partnership (EDCTP)
2000 - 2006 President, Vienna School of Clinical Research
2003 - 2005 Course Director, Health Outcomes Research Training, Vienna School of Clinical Research
2002 - 2005 Member, International Forum on Medicines (established by initiative of the International Pharmaceutical Federation; FIP)
1996 - 2005 Member, Drug Advisory Board, Austrian Ministry of Health
1997 - 2003 Member, Scientific Advisory Board on Gene Therapy, Austrian Ministry of Health
2002 - 2003 Visiting Professor, Outcomes Research, Merck&Co, Inc., Whitehouse Station, NJ, USA
2001 - 2002 Member, Scientific Advisory Review Group (SciARG) at the European Agency for the Evaluation of Medicinal Products
2000 - 2002 Member, Committee for Orphan Medicinal Products (COMP) at the European Agency for the Evaluation of Medicinal Products
2000 - 2002 Board Member, Austrian Science Foundation
2000 - 2002 Chair, faculty committee on faculty promotion guidelines and curriculum development, Medical Faculty of the Unversity of Vienna
1992 - 2002 Chair, Department of Clinical Pharmacology, Medical University of Vienna
1999 - 2001 Chair, Permanent Advisory Board of the Austrian Ethics Committes
Education:
1979 - 1980 M.Sc., Toxicology, University of Surrey, Guildford, UK
1974 - 1979 M.D., Vienna University Medical School, Vienna, Austria
Publications:
Over 250 original articles in peer reviewed journals, several other papers,chapters in books, etc

FACULTY BIOGRAPHIES

Dirk Elewaut, M.D., Ph.D.

Dirk Elewaut is a full professor of rheumatology and immunology and chair of the Department of Rheumatology at Ghent University Hospital. He obtained his MD at Ghent University in 1991 and his PhD in 1997 at the same institution. Following postdoctoral research at the University of California San Diego and the La Jolla Institute for Allergy and Immunology, he joined the faculty of the Department of Rheumatology at Ghent University Hospital in 2001, a Center of Excellence of the European League Against Rheumatism (EULAR) and of the Federation of Clinical Immunological Societies (FOCIS). He has published more than 180 scientific publications, often in high impact journals, and is heading a team of 25 researchers. He is a member of the editorial board of several journals including Arthritis Research and Therapy. His research interests are centered around translational aspects of immune regulation to combat inflammatory arthritis and associated joint damage.

FACULTY BIOGRAPHIES

Wain Fishburn, J.D.

Wainwright Fishburn, Jr. is a founding partner of Cooley LLP's San Diego office, a prominent venture capital attorney, and chair of the firm's Digital Health group.

As a recognized life science and digital health thought-leader, Wain is a frequent speaker at programs addressing industry issues, including most recently at USC's Body Computing Conference, Impact Forum 2012, the Burrill & Company 2013 Digital Health Conference and the Wireless-Life Sciences Alliance's Convergence Summit.

Wain has specialized focus in the fields of therapeutics, molecular diagnostics, digital health and personalized medicine.
As both a founder and as counsel, Wain has worked with venture capital-backed life science companies across a variety of fields. For example, in the field of genomic medicine, he works with groups that develop and deploy high-performance network technology for genomic research and medicine. He is on the Board of the Critical Path Institute, an independent institute created in part by the FDA, dedicated to improving the regulatory path for innovative medical therapies.

As an active community leader, Wain is Chairman of the Sanford-Burnham Institute for Medical Research, one of the nation's leading independent biomedical research institutes. He is a founding director of both the Corporate Directors Forum and BIOCOM, the largest regional life science association in the world, representing more than 550 member companies and is a member of its Executive Committee.

Wain is a co- founder of seven companies, two of which are public. Prior to law school, he worked in the corporate environment assisting with M&A for 12 operating companies. He has a B.A. from the University of Arizona and completed post-graduate work as a Senior Fellow at the Australian National University. He received his J.D. degree from the University of California, Hastings College of the Law and served as President of the Hastings Board of Governors.

FACULTY BIOGRAPHIES

Pat Furlong, R.N., B.S., M.S.

Leading the fight to end duchenne

Pat Furlong is the Founding President and CEO of Parent Project Muscular Dystrophy (PPMD), the largest nonprofit organization in the United States solely focused on Duchenne muscular dystrophy (Duchenne). Their mission is to end Duchenne. They accelerate research, raise their voices in Washington, demand optimal care for all young men, and educate the global community.

Duchenne is the most common fatal, genetic childhood disorder, which affects approximately 1 out of every 3,500 boys each year worldwide. It currently has no cure.

When doctors diagnosed her two sons, Christopher and Patrick, with Duchenne in 1984, Pat didn't accept "there's no hope and little help" as an answer. Pat immersed herself in Duchenne, working to understand the pathology of the disorder, the extent of research investment and the mechanisms for optimal care. Her sons lost their battle with Duchenne in their teenage years, but she continues to fight—in their honor and for all families affected by Duchenne.

In 1994, Pat, together with other parents of young men with Duchenne, founded PPMD to change the course of Duchenne and, ultimately, to find a cure. Today, Pat continues to lead the organization and is considered one of the foremost authorities on Duchenne in the world.

FACULTY BIOGRAPHIES

Brian Goeltzenleuchter, M.F.A, Artist

Brian Goeltzenleuchter (b. 1976) is an artist based in San Diego, USA. His recent projects investigate the use-value of cultural objects and institutions. In 2001 Goeltzenleuchter received his MFA from the University of California, San Diego. From 2002 - 2008 he was Associate Professor of Art at Central Washington University. He is currently a Research Fellow at the Institute for Public and Urban Affairs at San Diego State University, and Artist-In-Residence at the Institute for Art and Olfaction in Los Angeles. His work has been screened, performed, and exhibited throughout the United States, Canada, Austria, Italy, China, Croatia, and the Netherlands.

Selected projects include: Sillage, Santa Monica Museum of Art (2014); Adaptive Equipment, Lust Gallery, Vienna, Austria (2011); c (pronounced /k/) Wellness Centre, Southern Alberta Art Gallery, Canada (2010); c Boutique, Museum of Contemporary Art, San Diego (2010); Sponge X Sponge, Colorado State University (2007); Institutional Wellbeing, Centrum Beeldende Kunst, The Netherlands (2006); Who's not for sale, Banff Centre, Canada (2006); Unpacking Iraq, International Festival of New Film/New Media Split, Croatia (2004)

FACULTY BIOGRAPHIES

Carol C. Gregorio, Ph.D.

Carol C. Gregorio, PhD, Professor and Department Head of Cellular and Molecular Medicine, Director of Molecular Cardiovascular Research Program and Co-Director of Sarver Heart Center, The University of Arizona

Dr. Gregorio built and currently directs the Molecular Cardiovascular Research Program (MCRP) at the University of Arizona. Researchers in the MCRP are focused on discovering and disseminating knowledge about the underlying biological and molecular mechanisms of heart development, heart function, heart disease and other malfunctions of the cardiovascular system. Their efforts emphasize translational research. A wide variety of interdisciplinary approaches are currently being used to address questions related to cardiovascular and skeletal muscle biology including developmental, physiological, cellular and molecular biology, genetics, bioengineering, biochemistry, proteomics, live-cell imaging, computational biology and bioinformatics. Dr. Gregorio herself runs an active and well-funded research program with a focus broadly summarized as understanding the cellular mechanisms involved in the assembly, regulation and maintenance of contractile proteins in cardiac and skeletal muscle in health and disease. Dr. Gregorio is an active member of several editorial and philanthropic boards, and is the current chair of a National Institutes of Health grant review study section. She received her Doctorate from Roswell Park Cancer Institute in Buffalo, NY with a major in Molecular Immunology, and did her postdoctoral fellowship at the Scripps Research Institute in La Jolla, CA.

FACULTY BIOGRAPHIES

David A. Hafler, M.D.

Dr. Hafler is the Gilbert H. Glaser Professor and Chairman, Department of Neurology, Yale School of Medicine and is the Neurologist-in-Chief of Yale-New Haven Hospital. He graduated magna cum laude in 1974 from Emory University with combined B.S. and M.Sc. degrees in biochemistry, and the University of Miami School of Medicine in 1978. He then completed his internship in internal medicine at Johns Hopkins followed by a neurology residency at Cornell Medical Center-New York Hospital in New York. Dr. Hafler received training in immunology at the Rockefeller University then at Harvard where he joined the faculty in 1984. He was one of the Executive Directors of the Program in Immunology at Harvard Medical School and was on the faculty of the Harvard-MIT Health Science and Technology program where he was actively involved in the training of graduate students and post-doctoral fellows. Dr. Hafler has been elected to membership in the American Society of Clinical Investigation, The American Neurological Association, the Alpha Omega Society, and was a Harvey Weaver Scholar of the National Multiple Sclerosis Society. He is currently a member of the editorial boards for Journal of Clinical Investigation and the Journal of Experimental Medicine, and is co-founder of the Federation of Clinical Immunology Societies. Dr. Hafler is a clinical scientist with a research interest in understanding the mechanism of autoimmunity with a particular interest in inflammatory central nervous system diseases, with over 300 publications in the field of autoimmunity and immunology. He received the 1st National Multiple Sclerosis five year Collaborative Center Award for tackling the MS genetic effort. Hafler leads the NIH Autoimmunity Prevention Center Grant at Yale, and was a Jacob Javits Merit Award Recipient from the NIH. His laboratory focuses on the understanding of human autoimmune diseases with the theme that investigation of naturally occurring human diseases give insight into the basic processes of T cell regulation, in addition to providing fundamental understanding and development of new therapies for human diseases. The laboratory has defined immunodominant epitopes of autoantigens, and has developed new technologies to measure both functionality and frequency of autoreactive T cells. More recently, Dr. Hafler has focused on broadly characterizing the molecular pathogenesis of the disease, both at the DNA, mRNA, and proteomic level. Dr. Hafler is a founding member of the International MS Genetic Consortium, a group recently formed to define the genetic causes of MS including scientists from University of Cambridge and University of California, San Francisco.

FACULTY BIOGRAPHIES

Janet Hafler, Ed.D

Janet Hafler is a Professor of Pediatrics and is the Associate Dean for Educational Scholarship at Yale University School of Medicine. As the Director of the Teaching and Learning Center her responsibilities include developing and implementing medical education and teaching and learning programs for faculty members, students and residents. Over her career she has nurtured a climate in teaching and learning where faculty and residents have been exposed to the cutting edge literature and ideas in medical education. She has focused on assisting faculty and residents in exploring innovative ways to effectively promote learning in both the classroom and clinical settings.

Promoting, influencing and nurturing a climate in which physicians, residents and students can teach — and learn — has been foremost among her career objectives. She has focused on providing an awareness of context for students, residents and faculty, urging them to be innovative in their many teaching environments and encouraging them to explore ways to understand how they can effectively promote learning in their interactions among themselves.

Dr. Hafler runs an active research program applying qualitative research methods in medical education. She collaborates with and mentors clinicians and faculty on the elements of qualitative research in the field of medical education and medical care. In turn, mentored faculty members have learned to develop and demonstrate the tools necessary to effectively teach and lead others. Dr. Hafler has published over 100 book chapters, curriculum materials and original articles in medical education and clinical journals. She has served as visiting professor internationally and has been invited to present regularly at regional and national professional meetings.

FACULTY BIOGRAPHIES

Matthias von Herrath, M.D.

Matthias von Herrath, M.D., traine din internal medicine in Freiburg, Germany and thereafter went to join Michael Oldstone at Scripps for a 4-year fellowship in Virology and Immunology. In 2008 he became director of the Diabetes Research Center at the La Jolla Institute for Allergy & Immunology.
Dr. von Herrath has made several key advances in the fight against type 1 diabetes and has been recognized on numerous occasions for his achievements. He is the recipient of the Juvenile Diabetes Research Foundation's prestigious Scholar Award and in 2008 received the Outstanding Scientific Achievement Award from the American Diabetes Association. He will receive the German Diabetes Association's Langerhand Preis in 2014.
Dr. von Herrath has more recently taken the reins of Novo Nordisk's new Type 1 Diabetes R&D Center in Seattle in 2011. His new position as the Center's Vice President and Head will allow him to realize his dream of playing a key role in clinical trials on potential type 1 diabetes treatments, while continuing some research activities focused on the pathology of type 1 diabetes at the La Jolla Institute on a part-time basis.

FACULTY BIOGRAPHIES

Paul Krieg, Ph.D.

Professor of Cellular and Molecular Medicine, University of Arizona College of Medicine.

Dr. Krieg carries out basic research investigating development of the cardiovascular system.

Dr. Krieg has many years of experience in molecular, cellular and developmental biology research. His laboratory focuses on development of the heart and blood vessels in the vertebrate embryo using the frog and chicken as model systems. In recent years studies have concentrated on transcriptional regulation of cardiovascular genes and on the signaling pathways regulating the patterning of embryonic blood vessels. Dr Krieg has published a broad range of articles in basic science journals and participates in national and international research meetings. He teaches basic molecular biology and early embryonic development to medical students in the University of Arizona College of Medicine. He has served on consulting boards for several Biotechnology companies in the US and has more than 20 years of experience reviewing grants on US National Institutes of Health grant review committees and other national and international grant review panels.

Dr. Krieg graduated with a PhD in Molecular Biology from the University of Adelaide in Australia and then carried out postdoctoral research at Harvard University. He established and independent research laboratory at the University of Texas at Austin in 1988 and then moved to the University of Arizona in 1999, where he is currently the Allan C. Hudson and Helen Lovaas Endowed Professor of the Sarver Heart Center.

FACULTY BIOGRAPHIES

Juan Carlos López, Ph.D.

Juan Carlos López was born in Oaxaca, México, in 1967. He obtained his first degree on Biomedical Research at the Universidad Nacional Autónoma de México, majoring in neuroscience. Juan Carlos got his Ph.D. degree from Columbia University (New York) in the laboratory of Eric Kandel, studying synaptic plasticity in neuronal cultures. He then carried out postdoctoral work at the Instituto Cajal (Madrid), studying presynaptic mechanisms of transmitter release. During this period, Juan Carlos wrote a book on the neurobiology of memory ("El Telar de la Memoria", Algar Editorial), with which he won the IV European Award of Scientific Dissemination in 1998. Two years later, Juan Carlos left experimental research to become Editor of Nature Reviews Neuroscience in London. In January 2004, he returned to New York to become the Chief Editor of Nature Medicine.

In February 2014, Juan Carlos left the publishing industry to become Head of Academic Relations and Collaborations at Hoffmann-La Roche. In this role, he and his team are charged with fostering interactions of his company with academic institutions worldwide with the aim of promoting the advance of translational research and the discovery of new medicines.
Juan Carlos has also served as a member of the Scientific Advisory Board and of the Board of Directors of Noscira, a Spanish biotechnology company interested in neurodegeneration, and a member of the Board of Directors of the Eureka Institute, an international initiative that aims to promote translational research by fostering the education of MDs and PhDs interested in bridging the gap between bench and bedside.

FACULTY BIOGRAPHIES

Giovanni Mariggi, Ph.D.

I have been part of the Index Ventures Life Sciences investment team since 2012. Index Ventures is a venture capital firm focused on life sciences and IT, with a dedicated life sciences fund that is actively being invested. Past biotech investments include Genmab, Micromet, Ariad, and Aegerion. My investment focus is on therapeutic projects involving small molecules, antibodies/ biologics and gene therapy to treat a variety of indications. Our work involves understanding whether projects that we are reviewing have strong scientific backing, a good clinical rationale and ultimately could translate into a marketed product and a successful investment. Much of my time is spent speaking with key opinion leaders both in academia and in industry to aid us in the assessment, along with the financial and legal aspects of the investment process.

Many of the companies we invest in are companies we spin-off from academic centers with the help of the founding inventors, reason for which we actively engage with the scientific community to discover where the next innovative treatments will be developed.

Prior to Index, I obtained a PhD in Biochemistry and Molecular Biology from University College London, performing doctoral work at Cancer Research UK's London Research Institute (formerly the Imperial Cancer Research Fund), focused on vascular biology and angiogenesis. Through my research expertise I was involved in consulting projects for biopharma clients to help determine the positioning of their products in clinical development.

FACULTY BIOGRAPHIES

Jan Vos van Marken, M.B.A.

Jan Vos van Marken (first name Jan Vos), 48 years old, was born near Amsterdam in the Netherlands and obtained his master in business administration at the University of Groningen. For his thesis he spent 5 months in Africa—Kinshasa, Congo to be precise—working out a feasibility study for a new Heineken bottling plant. In 1989 he started his career at the oil company Shell, where he held 5 different financial positions in 5 different Shell companies. After a serving as financial director at an internet start-up, AGENCY.COM for a few years, he decided to join University Medical Center Utrecht where he was the non-medical director of the laboratory and surgical divisions for 8 years. Currently he is director of UNOVATE, a holding company of the UMC Utrecht (www.unovate.nl), which focuses on healthcare service design and innovation; essentially everything that has nothing to do with intellectual property. In that role he became involved in the Eureka Institute for Translational Medicine of which he recently became a board member. He is also 'Innovation & Development Ambassador' of the UMC Utrecht, through which he developed the www.urekamegachallenge.nl, a competition for the development of innovative healthcare ideas.

People that are driven by their believes and the 'why question' (Simon Sinek's 'Golden circle') inspire Jan Vos. The goals of the Eureka Institute for Translational Medicine perfectly match with this.

Jan Vos married to Suzan in 1994. No kids. In his spare time Jan Vos loves mountaineering, speedskating, cycling, playing golf and squash, a bit of cooking and with their 150 year old farmhouse he needs to love construction, maintenance and gardening.

FACULTY BIOGRAPHIES

Andrew Marshall, Ph.D.

Andrew Marshall was appointed Chief Editor of Nature Biotechnology in 2000 after joining the journal in 1996. Since that time, the journal's impact factor has increased from 11.0 to 32.0. As well as frequently speaking about biotechnology research and translation at international meetings while walking in ever-decreasing circles, he also organizes conferences and symposia for the journal. He has more years of experience in scientific publishing than he would care to mention, particularly at a 'luxury' journal; previously, he was Editor of Current Opinion in Biotechnology from 1992 to 1996. He has written hundreds of articles and editorials of varying quality and interest and has contributed to the popular media, including The Economist and Popular Science, and for trade publications. In 2003, he launched Nature Biotechnology's free-access web portal Bioentrepreneur (www.nature.com/bioent) providing practical information and advice on the challenges of starting a biotechnology enterprise. Since 2007, he has been hosting the networking events termed SciCafés in Boston, San Francisco, San Diego, Houston, London and now New York, which showcase rising stars in academia to early-stage investors and industry R&D leaders. He obtained a BSc with Honors and his PhD and postdoctoral experience in molecular biology and microbiology at King's College London, where has was given the Helen White Prize, likely as a result of a clerical error.

FACULTY BIOGRAPHIES

Alberto Martini, M.D., Ph.D.

Alberto Martini is Professor of Pediatrics at the University of Genoa and Director of Pediatria II Reumatologia (EULAR Centre of Excellence in Rheumatology 2008-18) and of the Department of Pediatrics in the G Gaslini Institute, Genoa, Italy (albertomartini@ospedale-gaslini.ge.it).

He is President of the Pediatric Rheumatology European Society (PRES), Founder and Chairman of the Pediatric Rheumatology International Trial Organization (PRINTO), Chairman of the EULAR Standing Committee on Pediatric Rheumatology, Past President of the Italian Council of Academic Professor of Pediatrics (2008-2012). He is Co-Editor of Clinical and Experimental Rheumatology and Pediatric Rheumatology and member of the Editorial board of Annals of Rheumatic Diseases

Prof Martini is author of more than 350 papers published in peer reviewed journals and related to pediatric rheumatic diseases.

FACULTY BIOGRAPHIES

Frank Miedema, Ph.D.



Frank Miedema (1954) has served as Dean and Vice Chairman of the Board of the University Medical Centre Utrecht since January 2009. He studied biochemistry in Groningen and took a PhD at the University of Amsterdam on human T-cell function working at Sanquin Resarch and the Academic Medical Centre in Amsterdam. In 1996 Frank Miedema was appointed professor in immunology of AIDS at the Academic Medical Centre in Amsterdam / University of Amsterdam. In 1998 he became director of Sanquin Research. In 2004 he moved with his lab to the University Medical Centre Utrecht, became professor of Immunology and Head of the Department of Immunology. In January 2009 he joined the UMCU Board and became Dean of the Medical Faculty of University of Utrecht. Prof. Miedema served on many boards as well as review committees and editorial boards. He also published extensively on the pathogenesis of AIDS. His group focussed on the cause of progressive loss of immune function in HIV infection and has argued that not loss of cellular immunity but HIV-induced excessive innate immune activation causes AIDS. Since 1995 Frank Miedema has written about the social and economic aspects of modern science. His essays were published in 'Science 3.0, Real Science, Real Knowledge' (Amsterdam University Press, 2012). In 2010 he started, together with colleagues from the University of Utrecht and the University Medical Centre Utrecht, a PhD and M. Sc. course on scientific literacy under the title 'That thing called Science'. Frank Miedema is also one of the founders of the Science in Transition initiative, that believes that science is in need of fundamental reform (www.scienceintransition.nl/english).

FACULTY BIOGRAPHIES

Berent Prakken, M.D., Ph.D.

Berent Prakken (MD, PhD) is a professor of immunology and pediatrics at the Utrecht Medical Center Utrecht, the Netherlands. He is co-chair of the Center for Molecular and Cellular Intervention (www.cmci-utrecht.nl). Berent Prakken heads a translational research lab that focuses on regulation of inflammation and biomarker development in human inflammatory diseases. He and his group received various prestigious national and international awards and grants. The Prakken lab hosted a core facility for the Immune Tolerance Network of the NIH, and is an international expertise centre for the luminex technology. Prakken serves as an editor and associate editor of several journals including the Annals of Rheumatic Diseases and the European Journal of Immunology, and is a regular reviewer for most major journals in his field. Berent Prakken was among others chair of the standing committee of pediatric rheumatology in EULAR, and member of the PRES council and EULAR executive committee. He is member of the steering committee of UCAN (international federation facilitating biological research in arthritis) and (thanks to a 1 million euro grant from the Dutch Arthritis foundation) set up the first international platform for biological studies in arthritis (UCAN-U, www.ucan-u.org). Prakken is member of various (inter)national scientific advisory boards and member of the Dutch National Health Council (Gezondheidsraad). He is coordinator of EUTRAIN, an EU FP7 Marie Curie Integrated Training Network for translational research in pediatric rheumatology. Berent Prakken's personal commitment is to collaboration and training & education. Unconventional thinking and crossing traditional boundaries inspire him, just as his close friendship with Salvo Albani and the other board members of Eureka. As co-founder and board member he enjoys the journey on which Eureka is taking them.

FACULTY BIOGRAPHIES

Norman Rosenblum, M.D, FRCPC

Dr. Rosenblum is Professor of Pediatrics, Physiology, and Laboratory Medicine and Pathobiology at the University of Toronto. He served as Associate Chair of Pediatrics (Research), University of Toronto, from 2001-2008 and led the Canadian Child Health Clinician Scientist Program (CCHCSP) from its inception in 2002 to 2012. Currently, Dr. Rosenblum serves as Associate Dean, Physician Scientist Training, Faculty of Medicine, and Director of the Undergraduate MD/PhD Program and the Postgraduate Clinician Investigator Program at the U of T. In this role, he is leading reform of the educational pathway for physician scientists at the University of Toronto and is a frequent advisor on clinician scientist career development in Canada and beyond. He is the recipient of the Society for Pediatric Research 2010 Maureen Andrew Award in Mentoring. Dr. Rosenblum is also a Pediatric Nephrologist and Senior Scientist in Developmental and Stem Cell Biology at The Hospital for Sick Children. The focus of Dr. Rosenblum's research is molecular mechanisms that control formation of the normal and malformed mammalian kidney. Dr. Rosenblum is the recipient of the 2004 Aventis Pasteur Research Award, the American Pediatric Society inaugural 2006 Norman J. Siegel New Member Outstanding Science Award, the Kidney Foundation of Canada 2011 Medal for Research Excellence, and a Canada Research Chair in Developmental Nephrology (2005-2019). Dr. Rosenblum is a founding member of the EUREKA Institute for Translational Medicine and a teacher in the annual Certificate Course.

FACULTY BIOGRAPHIES

Vicki L. Seyfert-Margolis, Ph.D.

Vicki L. Seyfert-Margolis, Ph.D. founded My Own Med in January 2013, based on over two years of work on a database, web and mobile application platform technology for family based co-management of health.

Prior to this, Dr. Seyfert-Margolis was the Senior Advisor for Science Innovation and Policy in the Office of the Commissioner of the US Food and Drug Administration. Dr. Seyfert-Margolis began her tenure at FDA during the transition of the Obama administration. While at the FDA, she oversaw the development and execution of an agency wide strategic plan for regulatory science. Dr. Seyfert-Margolis worked with President Obama's Start-Up America and the White House Jobs Council to help shape policies to promote growth within the biotechnology sector of the US economy. She served as the lead FDA representative on the President's Council of Advisors of Science and Technology (PCAST) study "Propelling Innovation in Drug Discovery, Development and Evaluation".

Dr. Seyfert-Margolis also oversaw the design and development of both scientific approaches and policies for issues surrounding food safety, including spearheading efforts to develop testing for dispersant and petro-hydrocarbons in seafood following the Deep Water Horizon, mercury in fish guidelines, arsenic in juices and rice, and radiation level detection in foods following the nuclear accident in Fukushima, Japan.

Prior to the FDA, she served as Chief Scientific Officer at the Immune Tolerance Network (ITN), a non-profit consortium of researchers seeking new treatments for diseases of the immune system. At ITN, Dr. Seyfert-Margolis oversaw the development of over 20 leading edge assay development and centralized laboratory facilities, bringing them to GLP and CLIA compliance. She designed and implemented biomarker discovery studies for over 25 Phase II clinical trials across a broad array of immunologically mediated diseases including autoimmune disorders, allergy, and solid organ transplantation.

Dr. Seyfert-Margolis was also an Adjunct Associate Professor with the Department of Medicine at the University of California San Francisco. Prior to this, she served as Director of the Office of Innovative Scientific Research Technologies at the National Institute of Allergy and Infectious Diseases at NIH, where she worked to integrate emerging technologies into existing immunology and infectious disease programs.

Dr. Seyfert-Margolis completed her PhD in immunology at the University of Pennsylvania's School of Medicine, and her post-doctoral fellowship work at Harvard University and the National Cancer Institute.

FACULTY BIOGRAPHIES

Professor Soo Khee Chee, MBBS, MD, FRACS, FACS, FAMS

Director, National Cancer Centre Singapore
Senior Vice Dean, Clinical and Academic Faculty Affairs, Duke-NUS Graduate Medical School Deputy Group CEO, Research and Education, Singapore Health Services
Senior Consultant, Department of Surgical Oncology, National Cancer Centre Singapore
Visiting Senior Consultant, Department of Surgery, Singapore General Hospital
Professor of Surgery, Yong Loo Lin School of Medicine, National University of Singapore

After graduating from University of Singapore's Medical School in 1975, Prof Soo moved to Australia where he was a Resident and Registrar at the Prince of Wales-Prince Henry Hospitals in New South Wales.

Following that, he obtained his Fellowship of the Royal Australasian College of Surgeons in 1982.

Choosing to specialise in Head and Neck Surgery and Surgical Oncology, Prof Soo spent further time in that field at the Royal Marsden Hospital at the Memorial Sloan Kettering Cancer Center's Department of Surgery.

In 1988, Prof Soo returned to Singapore working at the Singapore General Hospital's Department of Surgery where he became the Head and Senior Consultant Surgeon between 1993 and 2004. He obtained his Doctor of Medicine from National University of Singapore in 1995.

As the Director of the National Cancer Centre Singapore, he provides strategic leadership to over 500 staff engaged in clinical care and research. In addition, Prof Soo holds the position of Senior Vice Dean of Clinical and Academic Faculty Affairs, Duke-NUS Graduate Medical School Singapore amongst many others.

He has trained international surgeons and has been Visiting Professor in the University of Toronto (Canada), Jaslok Hospital and Research Centre (Mumbai, India), as well as Stanford University Medical Center (USA). Prof Soo is also a Professor of Surgery at the National University of Singapore.

For his devotion to training and education, he was bestowed the Outstanding Teachers' Award and Best Teacher (Undergraduate) Award in 1996 and 2001 respectively. In 2003, Prof Soo was awarded the National Day Award, Public Administration Medal (Gold) for his contribution to the country. In 2008, he was awarded the National Outstanding Clinician Mentor Award, an inaugural National Medical Excellence Award conferred by the Ministry of Health. And in 2011, he was awarded the President's Science and Technology Medal in recognition for his contributions to Singapore's clinical service and healthcare landscape. He is currently the Benjamin Sheares Professor of Academic Medicine in Duke-NUS Graduate Medical School.
Prof Soo has wide ranging research interests in the conduct of clinical trials for new cancer treatments as well as in the field of biophotonics and its role as a new imaging modality for the early detection of cancer.

FACULTY BIOGRAPHIES

Anna van Suchtelen, M.Sc., Artist

Anna van Suchtelen (New York 1961) studied Literature (MA) in Groningen, the Netherlands and Visual Arts at University of California San Diego, USA. Over the years she professionally moved from literary editor to visual artist. Text and narrative play a crucial role in her visual work, which includes installations, audio works and film. Her projects, often context-specific and interactive, explore the senses, memory and time. Her work has been exhibited, performed and screened in the Netherlands, the United States, Canada, Italy, India and Japan.

Selected projects include: Our Airs Conspire, installation with heat, sound and breathing (2013) nominated by K.F. Hein Art Stipendium; Pilgrim Kootwijk, film (2013) and interactive walk (2012); I got life!, installation with shower curtain and soundtrack (2011); Lindenduft, installation with memory cupboards and film (2010); Soft Voices, installation with listening glasses and film (2009); Overtocht (Passing), film (2009) and performance on a ferry (2008).

http://www.annavansuchtelen-eng.kunstinzicht.nl/

FACULTY BIOGRAPHIES

Lucy Wedderburn, M.D., Ph.D.

Lucy Wedderburn is a Professor in Paediatric Rheumatology at UCL (Institute of Child Health) and a Consultant at Great Ormond Street Hospital (GOSH).

She trained in Cambridge and then London in Immunology and Rheumatology and then spent time training in science in the University of Stanford, USA, before returning to University College London (UCL) and GOSH on a Wellcome Trust Fellowship. She has been at GOSH for more than 10 years as a consultant. Lucy's research group investigates the mechanisms of childhood autoimmunity and what controls immune responses. She is the PI of two large international translational research networks in the field of Paediatric Rheumatology (in childhood arthritis, JIA and myositis, JDM) and has led the development of databases now being used to enhance clinical care, research and specifically efforts in stratified medicine. Her current work includes introduction of a new biomarker for prognostic use in JIA and integration of proteomic/genetic/transcriptome data for biomarker discovery (funded in part by a BRC- Industry partner grant, partner: Pfizer). She is Director of the Arthritis Research UK Centre for Adolescent Rheumatology at UCL ULCH and GOSH which aims to capacity build and enhance translational science in the field of Adolescent Rheumatology. Lucy has been involved with the Eureka program and has led the UCL involvement in this programme since 2009.



EUREKA

Institute

OBSERVER &

GUEST BIOGRAPHIES

EUREKA INSTITUTE™

for translational medicine

GUEST BIOGRAPHIE

Alison Buchan, PhD, FCAHS

Vice-Dean Research and International Relations,
Faculty of Medicine
Professor of Laboratory Medicine and Pathobiology
University of Toronto

Dr. Buchan joined the University of Toronto in 2011 as Vice-Dean and Professor in the Department of Laboratory Medicine and Pathobiology. At the UofT Alison has led a Faculty of Medicine wide consultation to formulate a new Research Strategic Plan for 2012 – 2017 with a core focus on Integration, Innovation and Impact (http://www.facmed.utoronto.ca/about/dean/strategic/Research_Strategic_Plan_2012-2017.htm). Researchers in the Faculty of Medicine and the Toronto Academic Health Sciences Network (TAHSN) brought in over $970 million in 2012-13, from Government, Charitable Foundations, Industry and Philanthropy to support innovative research. The TAHSN group brings together researchers at nine fully affiliated Academic Hospitals with the University of Toronto. The FoM has over 2000 active researchers spanning all areas health research from basic discovery sciences to health policy and outcomes studies. The integrating focus of this health research is to create new knowledge to improve the health of individuals and communities in a globally connected world.

In her previous position as Executive Associate Dean Research in the Faculty of Medicine at the University of British Columbia, Dr. Buchan was responsible for promoting and developing the UBC Faculty of Medicine's outstanding health and life sciences research. Alison fostered interdisciplinary, team-based research and was responsible for bringing together investigators to establish the Centre for Disease Modeling in the Life Sciences Centre. She also worked across six Faculties within UBC on the implementation of a new School of Population and Public Health. Prior to leaving Dr. Buchan was concentrating on expanding the Neurosciences, Mental Health and Addictions translational research cluster into an innovative Centre for Brain Health combining basic sciences, Neurology and Psychiatry. This Centre attracted the largest philanthropic donation to UBC at that time. Dr. Buchan is the recipient of the Canadian Physiological Society Sarrazin Lectureship, the highest award for the Society. She has made many significant contributions to the field of human cell biology, and was elected to the Canadian Academy of Health Sciences in 2009.

OBSERVER BIOGRAPHIES

Sumita Anant, PhD, CBCI

Associate Director, Clinical Sciences, Head AMRI Administration and Deputy Head, Lab Sciences Core
Email: sumita.anant@duke-nus.edu.sg

Dr Sumita Anant is involved in planning of new programs and initiatives, program management, and engagement and communication with the Academic Medicine community at Duke-NUS and SingHealth. She manages the grant pre-review program, academic visits to AMRI and provides overall administrative oversight of AMRI. She also serves as the Deputy Head of AMRI's Laboratory Sciences Coordination Core which fosters links between clinician scientists and basic scientists. Dr Anant completed her Bachelors and Masters in Microbiology, MS University, and PhD in Biotechnology from the National Centre for Biological Sciences, India. Her postdoctoral studies at the Salk Institute, USA, focused on age-related cognitive decline in transgenic mouse models. She spent several years at NUS overseeing research operations at the Life Sciences Institute and building management at the Centre for Life Sciences; the institute won several safety awards and the Centre served as a model for other new multi-organizational research buildings in NUS. She also played a vital role in the planning, establishment and operations of research laboratories of the NUS Environmental Research Institute and management and expansion of its research collaborations.

Joseph Ferenbok, Ph.D.

Joseph Ferenbok, is an Assistant Professor in the Department of Surgery, Division of Anatomy at the Faculty of Medicine at the University of Toronto. He has served as the Assistant Director of the Knowledge Media Design Institute and the Director of the Collaborative Program in Knowledge Media Design, and is currently the Director of the Translational Research Program in Health Science in the Institute of Medical Science at the University of Toronto. His teaching interests centre on the translation and mobilization of knowledge across disciplinary contexts using design thinking strategies among multidisciplinary and interdisciplinary teams. His teaching has spanned media design, legal issues in developing technologies, innovation and commercialization strategies and interdisciplinary collaboration for knowledge translation and mobilization. His research centres on information privacy and video surveillance. The Principal Investigator of the "Who is Watching You? And Why?" project funded by the Office of the Privacy Commissioner of Canada, Joseph's research group is investigating citizen's awareness and concerns about the changing nature of surveillance technologies, practices, and policies. His research interests also involve the development of biometrics and facial recognition technology and their growing role in institutional identification practices.

OBSERVER BIOGRAPHIES

Alan Landay, PH.D.

Dr. Alan Landay is Professor and Chairman of the Department of Immunology/Microbiology at Rush University Medical Center in Chicago. He has been involved in HIV research for over 30 years having performed some of the first immune evaluations of HIV infected haemophiliacs in 1982 while completing a postdoctoral fellowship at the University of Alabama, Birmingham. Dr. Landay joined the faculty at Rush University Medical Center in 1983 and helped establish the HIV research program which has grown to encompass both a basic and translational focus on immune studies in HIV. Dr. Landay served as Chair of the National Committee of Clinical Laboratory Standards Committee on Flow Cytometry which produced the first national standard on CD4 testing. He has also served as an advisor to the College of American Pathologists, NIH and WHO on Standardization of CD4 Testing and serves on the Bill and Melinda Gates Foundation Global Health Care Technologies Committee. Dr. Landay's current research focus is on immune pathogenesis, mucosal immunity and immune based therapy of HIV and associated diseases. Dr. Landay is Chair of the NIH Office of AIDS Research Panel on Pathogenesis and PI of the Chicago Developmental Center for AIDS Research and serves on the Office of AIDS Research HIV and Aging Committee. He serves on NIH, AmFar, Glazer Pediatric AIDS Foundation and State of California Grant grant review panels and is past Chair of the NIH HIV Vaccine Study Section. He has served as a Visiting Professor at the University of Utrecht where he focused on studies of food and pharma in animal models and translated them to human studies. He has served as a mentor for over 15 graduate students and postdoctoral fellows who have gone on to obtain academic positions. Dr. Landay has published over 325 peer reviewed papers focused on the role of immune activation inflammation, and mucosal immune responses in HIV pathogenesis and therapy.

Rebecca Ludwig, Ph.D

Rebecca Ludwig did her PhD at the Max-Planck-Institute for marine Microbiology in Bremen, Germany working on hypersaline microbial mats. After her PhD she worked as a project manager for international projects. Rebecca was part of the management team which set-up the European Research Infrastructure for translational Medicine – EATRIS. She complemented her experience by studying Human Resources Development at the Technical University Braunschweig and is now the Education & Training Manager of EATRIS. She also works for the IMI (Innovative Medicine Initiative) Education & Training project EMTRAIN. EMTRAIN is a pan-European platform of 15 pharmaceutical companies and 10 academic research institutions covering training and education from basic science through clinical development to pharmacovigilance. In EMTRAIN Rebecca is co-leading the development of a platform to exchange innovative and goal-oriented teaching methodologies.

OBSERVER BIOGRAPHIES

Gerard Pasterkamp, M.D., Ph.D

Gerard Pasterkamp, MD, is Professor of Experimental Cardiology, Division Heart and Lungs, UMCU. His research interests are in the field of cardiovascular biology and more specifically innovation in biomarkers. He is the applicant of the CTMM Circulating Cell proposal that was granted in the first evaluation rounds. Private public research projects are one of the main core-activities within the laboratory of experimental cardiology. In the UMCU he is a member of the focus theme "Innovation and Valorisation". In this theme he established the Valorisation track: a system to appreciate the efforts of biomedical researchers not just based on publications and citations, but based on innovation strength and device development. Recently he initiated with 6 other founders from 3 Universities an inter-academic office that will act as a science broker specialized in the field of cardiovascular biomarkers. Objective of this office is to create a strong portfolio including Dutch research facilities and knowledge that will be exposed to international global operating Pharma and Diagnostic companies.